Cohort | |
Number of patients | 22 |
Number of collections | 40 |
Sex | |
Female | 22 (100%) |
Pathology | |
IDC | 18 (81.8%) |
ILC | 4 (18.2%) |
Histologic subtype | |
HR+, HER2− | 17 (77.3%) |
HR−, HER2+ | 1 (4.5%) |
HR+, HER2+ | 1 (4.5%) |
TNBC | 3 (13.6%) |
Clinical subtype | |
IBC | 6 (27.3%) |
Non-IBC | 16 (72.7%) |
Prior therapies in metastatic setting | 2* [0–7] |
Sites of disease | |
Bone | 18 (81.8%) |
Visceral | 15 (68.2%) |
CTC clusters | |
Yes | 8 (36.4%) |
No | 14 (63.6%) |
Total blood draws with clusters | 14 (35.0%) |